BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-60. [PMID: 32272208 DOI: 10.1016/j.annonc.2020.03.304] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 43.0] [Reference Citation Analysis]
Number Citing Articles
1 Clift AK, Frilling A. Liver-Directed Therapies for Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:44. [PMID: 33721122 DOI: 10.1007/s11912-021-01030-0] [Reference Citation Analysis]
2 Lai J, Huang Y, Wu J, Cheng H, Qiu F. Multiple endocrine neoplasia type 1 involving both the liver and lung: a case report. World J Surg Oncol 2022;20:151. [PMID: 35538538 DOI: 10.1186/s12957-022-02622-1] [Reference Citation Analysis]
3 Li S, Niu M, Deng W, Li N, Wei C, Zhang C, Luo S. Efficacy of Chemotherapy versus Transcatheter Arterial Chemoembolization in Patients with Advanced Primary Hepatic Neuroendocrine Carcinoma and an Analysis of the Prognostic Factors: A Retrospective Study. Cancer Manag Res 2021;13:9085-93. [PMID: 34916851 DOI: 10.2147/CMAR.S343572] [Reference Citation Analysis]
4 Garcia-Alvarez A, Cubero JH, Capdevila J. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms? Curr Oncol Rep 2022. [PMID: 35171460 DOI: 10.1007/s11912-022-01235-x] [Reference Citation Analysis]
5 Young K, Lawlor RT, Ragulan C, Patil Y, Mafficini A, Bersani S, Antonello D, Mansfield D, Cingarlini S, Landoni L, Pea A, Luchini C, Piredda L, Kannan N, Nyamundanda G, Morganstein D, Chau I, Wiedenmann B, Milella M, Melcher A, Cunningham D, Starling N, Scarpa A, Sadanandam A. Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours. Gut 2021;70:1904-13. [PMID: 32883872 DOI: 10.1136/gutjnl-2020-321016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
6 Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. Curr Treat Options Oncol 2021;22:73. [PMID: 34185197 DOI: 10.1007/s11864-021-00863-y] [Reference Citation Analysis]
7 Kaçmaz E, Klümpen HJ, Bemelman WA, Nieveen van Dijkum EJM, Engelsman AF, Tanis PJ. Evaluating Nationwide Application of Minimally Invasive Surgery for Treatment of Small Bowel Neuroendocrine Neoplasms. World J Surg 2021;45:2463-70. [PMID: 33783584 DOI: 10.1007/s00268-021-06036-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Krawczyk N, Röwer R, Anlauf M, Muntanjohl C, Baldus SE, Neumann M, Banys-Paluchowski M, Otten S, Luczak K, Ruckhäberle E, Mohrmann S, Hoffmann J, Kaleta T, Jaeger B, Esposito I, Fehm T. Invasive Breast Carcinoma with Neuroendocrine Differentiation: A Single-Center Analysis of Clinical Features and Prognosis. Geburtshilfe Frauenheilkd 2022;82:68-84. [PMID: 35027862 DOI: 10.1055/a-1557-1280] [Reference Citation Analysis]
9 Abdel-Rahman O, Pham TM, Pokhrel A, Ruether D, Sawyer MB. Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years: A Real-World Study. Am J Clin Oncol 2022. [PMID: 35383575 DOI: 10.1097/COC.0000000000000906] [Reference Citation Analysis]
10 Lindner K, Binte D, Hoeppner J, Wellner UF, Schulte DM, Schmid SM, Luley K, Buchmann I, Tharun L, Keck T, Gebauer J, Kulemann B. Resection of Non-Functional Pancreatic Neuroendocrine Neoplasms-A Single-Center Retrospective Outcome Analysis. Curr Oncol 2021;28:3071-80. [PMID: 34436034 DOI: 10.3390/curroncol28040268] [Reference Citation Analysis]
11 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer 2021;146:56-73. [PMID: 33588146 DOI: 10.1016/j.ejca.2021.01.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
13 Takagi K, Umeda Y, Yoshida R, Yoshida K, Yasui K, Sato H, Yagi T, Fujiwara T. Gastroenteropancreatic neuroendocrine tumor of the accessory papilla of the duodenum: a case report. Surg Case Rep 2021;7:156. [PMID: 34191176 DOI: 10.1186/s40792-021-01241-4] [Reference Citation Analysis]
14 Uchima H, Diez-Caballero A, Capdevila J, Rosinach M, Mata A, Turró R, Espinós J. Underwater endoscopic mucosal resection for en bloc resection of a neuroendocrine tumor in the duodenal bulb. Endoscopy 2021. [PMID: 34144620 DOI: 10.1055/a-1512-8954] [Reference Citation Analysis]
15 Müller C, Kreissl MC, Klose S, Krause A, Keitel V, Venerito M. Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. Medicine (Baltimore) 2022;101:e28610. [PMID: 35089197 DOI: 10.1097/MD.0000000000028610] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Vida Navas EM, Martínez Lorca A, Sancho Gutiérrez A, Sanz Gómez L, Navarro Martínez T, Grande Pulido E, Carrato Mena A, Gajate Borau P. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:676973. [PMID: 33935979 DOI: 10.3389/fendo.2021.676973] [Reference Citation Analysis]
17 Hiltunen N, Rintala J, Väyrynen JP, Böhm J, Karttunen TJ, Huhta H, Helminen O. Monocarboxylate Transporters 1 and 4 and Prognosis in Small Bowel Neuroendocrine Tumors. Cancers 2022;14:2552. [DOI: 10.3390/cancers14102552] [Reference Citation Analysis]
18 Das S, Al-Toubah T, Strosberg J. Chemotherapy in Neuroendocrine Tumors. Cancers (Basel) 2021;13:4872. [PMID: 34638356 DOI: 10.3390/cancers13194872] [Reference Citation Analysis]
19 Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.Diagnostics (Basel). 2020;10. [PMID: 33297381 DOI: 10.3390/diagnostics10121059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
20 Shi M, Fan Z, Xu J, Yang J, Li Y, Gao C, Su P, Wang X, Zhan H. Gastroenteropancreatic neuroendocrine neoplasms G3: Novel insights and unmet needs. Biochim Biophys Acta Rev Cancer 2021;1876:188637. [PMID: 34678439 DOI: 10.1016/j.bbcan.2021.188637] [Reference Citation Analysis]
21 Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel) 2021;11:605. [PMID: 33805264 DOI: 10.3390/diagnostics11040605] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. Cancer Res Treat 2021;53:291-300. [PMID: 33421978 DOI: 10.4143/crt.2020.1233] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Caplin ME. Can the peptide receptor radionuclide therapy [177Lu]Lu-DOTA-TATE provide a net benefit for NET patients? EJC Suppl 2021;16:1-4. [PMID: 34912477 DOI: 10.1016/j.ejcsup.2021.06.001] [Reference Citation Analysis]
24 Pellat A, Cottereau AS, Palmieri LJ, Soyer P, Marchese U, Brezault C, Coriat R. Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. Cancers (Basel) 2021;13:2448. [PMID: 34070035 DOI: 10.3390/cancers13102448] [Reference Citation Analysis]
25 Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med 2020;9:E2468. [PMID: 32752158 DOI: 10.3390/jcm9082468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
26 Taboada RG, Riechelmann RP, Mauro C, Barros M, Hubner RA, Mcnamara MG, Lamarca A, Valle JW. Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. The Oncologist 2022. [DOI: 10.1093/oncolo/oyab024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Opalińska M, Sowa-staszczak A, Al Maraih I, Gilis-januszewska A, Hubalewska-dydejczyk A. Peptide receptor radionuclide therapy as a tool for the treatment of severe hypoglycemia in patients with primary inoperable insulinoma. Bio-Algorithms and Med-Systems 2022;17:221-6. [DOI: 10.1515/bams-2021-0138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Costanzo A, Canziani M, Ferrari CC, Bertocchi V, Cutaia S, Bucci EO, Uslenghi E, Ferretti A, De Luca M, Ceriani F. An apparent primitive mass of the mesentery: A case report. Medicine (Baltimore) 2022;101:e29464. [PMID: 35713456 DOI: 10.1097/MD.0000000000029464] [Reference Citation Analysis]
29 Gallo C, Rossi RE, Cavalcoli F, Barbaro F, Boškoski I, Invernizzi P, Massironi S. Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance. World J Gastroenterol 2022; 28(11): 1123-1138 [DOI: 10.3748/wjg.v28.i11.1123] [Reference Citation Analysis]
30 Harrow B, Fagnani F, Nevoret C, Truong-Thanh XM, de Zélicourt M, de Mestier L. Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting. Adv Ther 2022;39:1754-71. [PMID: 35190997 DOI: 10.1007/s12325-022-02060-1] [Reference Citation Analysis]
31 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Reference Citation Analysis]
32 Riss P, Scheuba K, Strobel O. [Endocrine and neuroendocrine tumors]. Chirurg 2021;92:996-1002. [PMID: 34618164 DOI: 10.1007/s00104-021-01512-8] [Reference Citation Analysis]
33 Tustumi F, Marques SSB, Barros EF, Henriques AC, Waisberg J, Dias AR. THE PROGNOSIS OF THE DIFFERENT ESOPHAGEAL NEUROENDOCRINE CARCINOMA SUBTYPES: A POPULATION-BASED STUDY. Arq Gastroenterol 2022;59:53-7. [DOI: 10.1590/s0004-2803.202200001-10] [Reference Citation Analysis]
34 Scalorbi F, Argiroffi G, Baccini M, Gherardini L, Fuoco V, Prinzi N, Pusceddu S, Garanzini EM, Centonze G, Kirienko M, Seregni E, Milione M, Maccauro M. Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Sci Rep 2021;11:19490. [PMID: 34593940 DOI: 10.1038/s41598-021-99048-8] [Reference Citation Analysis]
35 Natalicchio A, Faggiano A, Zatelli MC, Argentiero A, D'Oronzo S, Marrano N, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi R, Ferrari P, Gori S, Morviducci L, Russo A, Tuveri E, Montagnani M, Gallo M, Silvestris N, Giorgino F. Metabolic disorders and gastroenteropancreatic-neuroendocrine tumors (GEP-NETs): How do they influence each other? An Italian Association of Medical Oncology (AIOM)/ Italian Association of Medical Diabetologists (AMD)/ Italian Society of Endocrinology (SIE)/ Italian Society of Pharmacology (SIF) multidisciplinary consensus position paper. Crit Rev Oncol Hematol 2021;:103572. [PMID: 34954047 DOI: 10.1016/j.critrevonc.2021.103572] [Reference Citation Analysis]
36 Broadbent R, Wheatley R, Stajer S, Jacobs T, Lamarca A, Hubner RA, Valle JW, Amir E, McNamara MG. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat Rev 2021;101:102299. [PMID: 34662810 DOI: 10.1016/j.ctrv.2021.102299] [Reference Citation Analysis]
37 Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, Yevich S, Joskin J, Gelli M, Barbé R, Lamartina L, Tissot H, Scoazec JY, Malka D, Ducreux M, Baudin E, de Baère T, Tselikas L. Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. Cancers (Basel) 2021;13:5366. [PMID: 34771531 DOI: 10.3390/cancers13215366] [Reference Citation Analysis]
38 Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, de Herder WW, Hörsch D, Knigge U, Korse CM, Lim E, Lombard-Bohas C, Pavel M, Scoazec JY, Sundin A, Berruti A;  ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021;32:439-451. [PMID: 33482246 DOI: 10.1016/j.annonc.2021.01.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
39 Shannon AB, Straker RJ, Fraker DL, Miura JT, Karakousis GC. Validated Risk-Score Model Predicting Lymph Node Metastases in Patients with Non-Functional Gastroenteropancreatic Neuroendocrine Tumors. Journal of the American College of Surgeons 2022;234:900-9. [DOI: 10.1097/xcs.0000000000000144] [Reference Citation Analysis]
40 Una Cidon E. Vasoactive intestinal peptide secreting tumour: An overview. World J Gastrointest Oncol 2022; 14(4): 808-819 [DOI: 10.4251/wjgo.v14.i4.808] [Reference Citation Analysis]
41 Butz H, Blair J, Patócs A. Molecular genetic testing strategies used in diagnostic flow for hereditary endocrine tumour syndromes. Endocrine 2021;71:641-52. [PMID: 33570725 DOI: 10.1007/s12020-021-02636-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175 [DOI: 10.3748/wjg.v28.i20.2163] [Reference Citation Analysis]
43 Hackeng WM, Assi HA, Westerbeke FH, Brosens LA, Heaphy CM. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.05.007] [Reference Citation Analysis]
44 Levy S, Verbeek WH, Eskens FA, van den Berg JG, de Groot DJA, van Leerdam ME, Tesselaar ME. First-line everolimus and cisplatin in patients with advanced extrapulmonary neuroendocrine carcinoma: a nationwide phase 2 single-arm clinical trial. Ther Adv Med Oncol 2022;14:175883592210770. [DOI: 10.1177/17588359221077088] [Reference Citation Analysis]
45 Lewandowski RJ, Toskich BB, Brown DB, El-Haddad G, Padia SA. Role of Radioembolization in Metastatic Neuroendocrine Tumors. Cardiovasc Intervent Radiol 2022. [PMID: 35918431 DOI: 10.1007/s00270-022-03206-y] [Reference Citation Analysis]
46 Liu Y, Liu H, Chen W, Yu H, Yao W, Fan W, Li J, Chen M, Chen J, Wang Y. Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden. Cancer Med 2022. [PMID: 35289113 DOI: 10.1002/cam4.4628] [Reference Citation Analysis]
47 Martínez-Galán J, Rodriguez I, Caba O. Importance of BRCA mutation for the current treatment of pancreatic cancer beyond maintenance. World J Gastroenterol 2021; 27(39): 6515-6521 [PMID: 34754149 DOI: 10.3748/wjg.v27.i39.6515] [Reference Citation Analysis]
48 Ambrosini V, Zanoni L, Filice A, Lamberti G, Argalia G, Fortunati E, Campana D, Versari A, Fanti S. Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers (Basel) 2022;14:1055. [PMID: 35205805 DOI: 10.3390/cancers14041055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kaewput C, Vinjamuri S. Role of Combined 68Ga DOTA-Peptides and 18F FDG PET/CT in the Evaluation of Gastroenteropancreatic Neuroendocrine Neoplasms. Diagnostics 2022;12:280. [DOI: 10.3390/diagnostics12020280] [Reference Citation Analysis]
50 Jeong H, Shin J, Jeong JH, Kim KP, Hong SM, Kim YI, Ryu JS, Ryoo BY, Yoo C. Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study. ESMO Open 2021;6:100119. [PMID: 33901869 DOI: 10.1016/j.esmoop.2021.100119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Xu S, Ye C, Chen R, Li Q, Ruan J. The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:2911. [PMID: 35740577 DOI: 10.3390/cancers14122911] [Reference Citation Analysis]
52 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Reference Citation Analysis]
53 Abdelmalak R, Lythgoe MP, Evans J, Flynn M, Waters J, Webb A, Pinato DJ, Sharma R. Exploration of Novel Prognostic Markers in Grade 3 Neuroendocrine Neoplasia. Cancers (Basel) 2021;13:4232. [PMID: 34439386 DOI: 10.3390/cancers13164232] [Reference Citation Analysis]
54 Pavel M, Ćwikła JB, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Capdevila J, Panzuto F, Truong Thanh XM, Houchard A, Ruszniewski P. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur J Cancer 2021;157:403-14. [PMID: 34597974 DOI: 10.1016/j.ejca.2021.06.056] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Wang Y, Hu X, Shi S, Song C, Wang L, Yuan J, Lin Z, Cai H, Feng ST, Luo Y. Utility of Quantitative Metrics from Dual-Layer Spectral-Detector CT for Differentiation of Pancreatic Neuroendocrine Tumor and Neuroendocrine Carcinoma. AJR Am J Roentgenol 2022. [PMID: 35043668 DOI: 10.2214/AJR.21.27017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Magi L, Rinzivillo M, Panzuto F. What Gastroenterologists Should Know about Carcinoid Syndrome. Gastroenterology Insights 2022;13:127-38. [DOI: 10.3390/gastroent13010014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Partelli S, Sclafani F, Barbu ST, Beishon M, Bonomo P, Braz G, de Braud F, Brunner T, Cavestro GM, Crul M, Trill MD, Ferollà P, Herrmann K, Karamitopoulou E, Neuzillet C, Orsi F, Seppänen H, Torchio M, Valenti D, Zamboni G, Zins M, Costa A, Poortmans P. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. Cancer Treat Rev 2021;99:102208. [PMID: 34238640 DOI: 10.1016/j.ctrv.2021.102208] [Reference Citation Analysis]
58 Falconi M, Fazio N, Ferone D, Versari A. Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Expert Opin Pharmacother 2020;21:2317-24. [PMID: 32990061 DOI: 10.1080/14656566.2020.1810237] [Reference Citation Analysis]
59 Wedin M, Mehta S, Angerås-Kraftling J, Wallin G, Daskalakis K. The Role of Serum 5-HIAA as a Predictor of Progression and an Alternative to 24-h Urine 5-HIAA in Well-Differentiated Neuroendocrine Neoplasms. Biology (Basel) 2021;10:76. [PMID: 33494283 DOI: 10.3390/biology10020076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Abdel-Rahman O, Ghosh S, Morrish D. Impact of baseline body mass index on the outcomes of patients with neuroendocrine neoplasms. J Endocrinol Invest 2022. [PMID: 35606667 DOI: 10.1007/s40618-022-01805-7] [Reference Citation Analysis]
61 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Modlin IM, Kidd M, Falconi M, Filosso PL, Frilling A, Malczewska A, Toumpanakis C, Valk G, Pacak K, Bodei L, Öberg KE. A multigenomic liquid biopsy biomarker for neuroendocrine tumor disease outperforms CgA and has surgical and clinical utility. Ann Oncol 2021:S0923-7534(21)03975-2. [PMID: 34390828 DOI: 10.1016/j.annonc.2021.08.1746] [Reference Citation Analysis]
63 Maldonado-García EL, Álvarez-Barragán AF, Acevedo-Aguirre CE, Galicia-Alemán B, Arellano-Gutiérrez G. Neuroendocrine tumor of the ileocecal valve: A case report and review of the literature. Rev Gastroenterol Mex (Engl Ed) 2021:S2255-534X(21)00123-7. [PMID: 34794925 DOI: 10.1016/j.rgmxen.2021.11.008] [Reference Citation Analysis]
64 Puliani G, Chiefari A, Mormando M, Bianchini M, Lauretta R, Appetecchia M. New Insights in PRRT: Lessons From 2021. Front Endocrinol 2022;13:861434. [DOI: 10.3389/fendo.2022.861434] [Reference Citation Analysis]
65 Bartolomei M, Berruti A, Falconi M, Fazio N, Ferone D, Lastoria S, Pappagallo G, Seregni E, Versari A. Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers (Basel) 2022;14:2501. [PMID: 35626105 DOI: 10.3390/cancers14102501] [Reference Citation Analysis]
66 Kaliszewski K, Ludwig M, Greniuk M, Mikuła A, Zagórski K, Rudnicki J. Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). Cancers (Basel) 2022;14:2028. [PMID: 35454934 DOI: 10.3390/cancers14082028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
67 Luecke S, Fottner C, Lahner H, Jann H, Zolnowski D, Quietzsch D, Grabowski P, Cremer B, Maasberg S, Pape UF, Mueller HH, Gress TM, Rinke A, The Members Of The German Net Registry. Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. Cancers (Basel) 2022;14:2718. [PMID: 35681701 DOI: 10.3390/cancers14112718] [Reference Citation Analysis]
68 Koumarianou A, Kaltsas GA, Chatzellis E, Kyriakopoulos G, Kolomodi D, Alexandraki KI. Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine 2021;73:232-9. [PMID: 33544352 DOI: 10.1007/s12020-021-02639-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Lee ONY, Tan KV, Tripathi V, Yuan H, Chan WW, Chiu KWH. The Role of 68Ga-DOTA-SSA PET/CT in the Management and Prediction of Peptide Receptor Radionuclide Therapy Response for Patients With Neuroendocrine Tumors: A Systematic Review and Meta-analysis. Clin Nucl Med 2022. [PMID: 35485851 DOI: 10.1097/RLU.0000000000004235] [Reference Citation Analysis]
70 Wessling J, Schreyer A, Grenacher L, Juchems M, Ringe K. [Incidental and "leave me alone" findings of the GI tract-part 2 : Intestinal wall and mesentery]. Radiologe 2022. [PMID: 35088094 DOI: 10.1007/s00117-021-00964-7] [Reference Citation Analysis]
71 Shah D, Lamarca A, Valle JW, McNamara MG. The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. J Clin Med 2021;10:403. [PMID: 33494364 DOI: 10.3390/jcm10030403] [Reference Citation Analysis]
72 Modlin IM, Kidd M, Frilling A, Falconi M, Filosso PL, Malczewska A, Kitz A. Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Ann Surg 2021;274:481-90. [PMID: 34183517 DOI: 10.1097/SLA.0000000000005026] [Reference Citation Analysis]
73 Kankava K, Maisonneuve P, Mangogna A, Centonze G, Cattaneo L, Prinzi N, Pusceddu S, Fazio N, Pisa E, Di Domenico S, Bertani E, Mazzaferro V, Albertelli M, Grillo F, Milione M. Prognostic features of gastro-entero-pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties. J Neuroendocrinol 2021;33:e13000. [PMID: 34268808 DOI: 10.1111/jne.13000] [Reference Citation Analysis]
74 Yan H, Yin L, Han H, Jin Y, Liu Z. Relationship between Primary Tumor Resection for Metastatic Small Intestine Neuroendocrine Tumors and Survival: A Propensity Score-Matched Analysis. J Invest Surg 2022;:1-9. [PMID: 34991432 DOI: 10.1080/08941939.2021.2024306] [Reference Citation Analysis]
75 Jungels C, Karfis I. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma. Curr Opin Oncol 2021;33:33-9. [PMID: 33093336 DOI: 10.1097/CCO.0000000000000691] [Reference Citation Analysis]
76 Panagiotou E, Gomatou G, Trontzas IP, Syrigos N, Kotteas E. Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials. Clin Transl Oncol 2021. [PMID: 34363593 DOI: 10.1007/s12094-021-02688-5] [Reference Citation Analysis]
77 Sharma R, Slater S, Evans J, Martinez M, Ward C, Izadi H, Wernig F, Thomas R. ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs). BMC Cancer 2022;22:800. [PMID: 35858849 DOI: 10.1186/s12885-022-09859-9] [Reference Citation Analysis]
78 Ohmoto A, Fujiwara Y, Horita N, Nakano K, Takahashi S. Platinum-doublet chemotherapy for advanced gastroenteropancreatic neuroendocrine carcinoma: a systematic review and meta-analysis. Discov Onc 2022;13. [DOI: 10.1007/s12672-022-00499-w] [Reference Citation Analysis]
79 Pantelis AG, Panagopoulou PA, Lapatsanis DP. Artificial Intelligence and Machine Learning in the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms—A Scoping Review. Diagnostics 2022;12:874. [DOI: 10.3390/diagnostics12040874] [Reference Citation Analysis]
80 Cuny T, van Koetsveld PM, Mondielli G, Dogan F, de Herder WW, Barlier A, Hofland LJ. Reciprocal Interactions between Fibroblast and Pancreatic Neuroendocrine Tumor Cells: Putative Impact of the Tumor Microenvironment. Cancers 2022;14:3481. [DOI: 10.3390/cancers14143481] [Reference Citation Analysis]
81 La Salvia A, Portigliatti Pomeri A, Persano I, Trevisi E, Parlagreco E, Colombi N, Brizzi MP, Picci RL, Oliva F. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Compr Psychiatry 2021;109:152244. [PMID: 34120056 DOI: 10.1016/j.comppsych.2021.152244] [Reference Citation Analysis]
82 Abdel-Rahman O, Fazio N. Outcomes of small-cell versus large-cell gastroenteropancreatic neuroendocrine carcinomas: A population-based study. J Neuroendocrinol 2021;33:e12971. [PMID: 33870570 DOI: 10.1111/jne.12971] [Reference Citation Analysis]
83 Canakis A, Lee LS. Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Endosc 2022; 14(5): 267-290 [DOI: 10.4253/wjge.v14.i5.267] [Reference Citation Analysis]
84 Espinosa-Olarte P, La Salvia A, Riesco-Martinez MC, Anton-Pascual B, Garcia-Carbonero R. Chemotherapy in NEN: still has a role? Rev Endocr Metab Disord 2021;22:595-614. [PMID: 33843007 DOI: 10.1007/s11154-021-09638-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
85 Siebenhüner AR, Langheinrich M, Friemel J, Schäfer N, Eshmuminov D, Lehmann K. Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor. Cancers (Basel) 2022;14:1478. [PMID: 35326628 DOI: 10.3390/cancers14061478] [Reference Citation Analysis]
86 Wang Y, Zhang L, Yang Y, Lu S, Chen H. Progress of Gastric Cancer Surgery in the era of Precision Medicine. Int J Biol Sci 2021;17:1041-9. [PMID: 33867827 DOI: 10.7150/ijbs.56735] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Artigas C, Mileva M, Flamen P, Karfis I. Targeted radionuclide therapy: an emerging field in solid tumours. Curr Opin Oncol 2021;33:493-9. [PMID: 34183491 DOI: 10.1097/CCO.0000000000000762] [Reference Citation Analysis]
88 Papadakis GZ, Karantanas AH, Marias K, Millo C. Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Eur J Radiol 2021;143:109932. [PMID: 34482177 DOI: 10.1016/j.ejrad.2021.109932] [Reference Citation Analysis]
89 Kiesewetter B, Raderer M. How I treat neuroendocrine tumours. ESMO Open 2020;5:e000811. [PMID: 32817134 DOI: 10.1136/esmoopen-2020-000811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
90 Koumarianou A, Daskalakis K, Tsoli M, Kaltsas G, Pavel M. Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. J Neuroendocrinol 2022;:e13174. [PMID: 35794780 DOI: 10.1111/jne.13174] [Reference Citation Analysis]
91 Feng LH, Su T, Lu Y, Ren S, Huang L, Qin X, Liao T. A model for predicting the overall survival of gastroenteropancreatic neuroendocrine neoplasms after surgery. Scand J Gastroenterol 2022;:1-8. [PMID: 35001789 DOI: 10.1080/00365521.2021.2024247] [Reference Citation Analysis]
92 Stankiewicz R, Grąt M. Current status of surgical management of patients with gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(4): 276-285 [DOI: 10.4240/wjgs.v14.i4.276] [Reference Citation Analysis]
93 Panteleev V, Davydenko P, Varava A, Raevskaya M, Kaldarov A. The role of calcium-stimulated venous sampling in the surgical treatment of multiple neuroendocrine neoplasms. Case report. Clin Endocrinol (Oxf) 2021. [PMID: 34278585 DOI: 10.1111/cen.14556] [Reference Citation Analysis]
94 Doornebal EJ, Harris N, Riva A, Jagatia R, Pizanias M, Prachalias A, Menon K, Preziosi M, Zamalloa A, Miquel R, Zen Y, Orford MR, Eaton S, Heaton N, Ramage J, Palma E, Srirajaskanthan R, Chokshi S. Human Immunocompetent Model of Neuroendocrine Liver Metastases Recapitulates Patient-Specific Tumour Microenvironment. Front Endocrinol 2022;13:909180. [DOI: 10.3389/fendo.2022.909180] [Reference Citation Analysis]
95 Fernandez CJ, Agarwal M, Pottakkat B, Haroon NN, George AS, Pappachan JM. Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. World J Gastrointest Surg 2021;13:231-55. [PMID: 33796213 DOI: 10.4240/wjgs.v13.i3.231] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
96 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Reference Citation Analysis]
97 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Reference Citation Analysis]
98 Zanini S, Renzi S, Giovinazzo F, Bermano G. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs). Front Endocrinol (Lausanne). 2020;11:562505. [PMID: 33304317 DOI: 10.3389/fendo.2020.562505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
99 Lim JY, Pommier RF. Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors. Front Endocrinol (Lausanne) 2021;12:622693. [PMID: 33732215 DOI: 10.3389/fendo.2021.622693] [Reference Citation Analysis]
100 Allmark A, Brubaker ML. Small cell neuroendocrine carcinoma disguised as an external hemorrhoid. JAAPA 2021;34:35-9. [PMID: 34320538 DOI: 10.1097/01.JAA.0000742960.70174.8d] [Reference Citation Analysis]
101 Ramdhani K, Braat AJAT. The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases. Cancers 2022;14:3415. [DOI: 10.3390/cancers14143415] [Reference Citation Analysis]
102 Jakob J, Salameh R, Wichmann D, Charalambous N, Zygmunt AC, Kreisel I, Heinz J, Ghadimi M, Ronellenfitsch U. Needle tract seeding and abdominal recurrence following pre-treatment biopsy of gastrointestinal stromal tumors (GIST): results of a systematic review. BMC Surg 2022;22:202. [PMID: 35597932 DOI: 10.1186/s12893-022-01648-2] [Reference Citation Analysis]
103 Fermi F, Andreasi V, Muffatti F, Crippa S, Tamburrino D, Partelli S, Falconi M. How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01200-8] [Reference Citation Analysis]
104 Rossi RE, Elvevi A, Citterio D, Coppa J, Invernizzi P, Mazzaferro V, Massironi S. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol 2021; 27(35): 5890-5907 [PMID: 34629807 DOI: 10.3748/wjg.v27.i35.5890] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
105 Wang WQ, Zhang WH, Gao HL, Huang D, Xu HX, Li S, Li TJ, Xu SS, Li H, Long J, Ye LY, Wu CT, Han X, Wang XH, Liu L, Yu XJ. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors. J Gastroenterol 2021;56:395-405. [PMID: 33742253 DOI: 10.1007/s00535-021-01777-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
106 Shi X, Li Y, Yuan Q, Tang S, Guo S, Zhang Y, He J, Zhang X, Han M, Liu Z, Zhu Y, Gao S, Wang H, Xu X, Zheng K, Jing W, Chen L, Wang Y, Jin G, Gao D. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nat Commun 2022;13:2169. [PMID: 35449156 DOI: 10.1038/s41467-022-29857-6] [Reference Citation Analysis]
107 Lu X, Yan S, Koral KA, Chen Z. Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors. Expert Rev Anticancer Ther 2021;21:917-26. [PMID: 34142932 DOI: 10.1080/14737140.2021.1944110] [Reference Citation Analysis]
108 Cox T, O'Connell M, Leeuwenkamp O, Palimaka S, Reed N. Real-world comparison of healthcare resource utilization and costs of [177Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the Hospital Episode Statistics dataset. Curr Med Res Opin 2022;:1-33. [PMID: 35418254 DOI: 10.1080/03007995.2022.2065146] [Reference Citation Analysis]
109 Juhlin CC, Falhammar H, Kjellman M, Åhlén J, Welin S, Calissendorff J. Highly proliferative anal neuroendocrine carcinoma: molecular and clinical features of a rare, recurrent case in complete remission. BMC Gastroenterol 2020;20:290. [PMID: 32854635 DOI: 10.1186/s12876-020-01433-6] [Reference Citation Analysis]
110 Lamberti G, La Salvia A. Neuroendocrine Tumors: Challenges and Future Perspectives. JCM 2022;11:4351. [DOI: 10.3390/jcm11154351] [Reference Citation Analysis]
111 Mollazadegan K, Welin S, Crona J. Systemic Treatment of Gastroenteropancreatic Neuroendocrine Carcinoma. Curr Treat Options Oncol 2021;22:68. [PMID: 34110508 DOI: 10.1007/s11864-021-00866-9] [Reference Citation Analysis]
112 Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V, Monterymard C, Lorgis V, Thuillier F, Baudin E, Scoazec JY, Lepage C, Desgrippes R. FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin. Dig Liver Dis 2021;53:824-9. [PMID: 33994125 DOI: 10.1016/j.dld.2021.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 Segaran N, Devine C, Wang M, Ganeshan D. Current update on imaging for pancreatic neuroendocrine neoplasms. World J Clin Oncol 2021; 12(10): 897-911 [PMID: 34733612 DOI: 10.5306/wjco.v12.i10.897] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Sundlöv A, Gleisner KS, Tennvall J, Ljungberg M, Warfvinge CF, Holgersson K, Hallqvist A, Bernhardt P, Svensson J. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients. Eur J Nucl Med Mol Imaging 2022. [PMID: 35451612 DOI: 10.1007/s00259-022-05786-w] [Reference Citation Analysis]
115 Pusceddu S, Prinzi N, Tafuto S, Ibrahim T, Filice A, Brizzi MP, Panzuto F, Baldari S, Grana CM, Campana D, Davì MV, Giuffrida D, Zatelli MC, Partelli S, Razzore P, Marconcini R, Massironi S, Gelsomino F, Faggiano A, Giannetta E, Bajetta E, Grimaldi F, Cives M, Cirillo F, Perfetti V, Corti F, Ricci C, Giacomelli L, Porcu L, Di Maio M, Seregni E, Maccauro M, Lastoria S, Bongiovanni A, Versari A, Persano I, Rinzivillo M, Pignata SA, Rocca PA, Lamberti G, Cingarlini S, Puliafito I, Ambrosio MR, Zanata I, Bracigliano A, Severi S, Spada F, Andreasi V, Modica R, Scalorbi F, Milione M, Sabella G, Coppa J, Casadei R, Di Bartolomeo M, Falconi M, de Braud F. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Netw Open 2022;5:e220290. [PMID: 35201309 DOI: 10.1001/jamanetworkopen.2022.0290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
116 Ito T, Masui T, Komoto I, Doi R, Osamura RY, Sakurai A, Ikeda M, Takano K, Igarashi H, Shimatsu A, Nakamura K, Nakamoto Y, Hijioka S, Morita K, Ishikawa Y, Ohike N, Kasajima A, Kushima R, Kojima M, Sasano H, Hirano S, Mizuno N, Aoki T, Aoki T, Ohtsuka T, Okumura T, Kimura Y, Kudo A, Konishi T, Matsumoto I, Kobayashi N, Fujimori N, Honma Y, Morizane C, Uchino S, Horiuchi K, Yamasaki M, Matsubayashi J, Sato Y, Sekiguchi M, Abe S, Okusaka T, Kida M, Kimura W, Tanaka M, Majima Y, Jensen RT, Hirata K, Imamura M, Uemoto S. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. J Gastroenterol 2021;56:1033-44. [PMID: 34586495 DOI: 10.1007/s00535-021-01827-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
117 Borbath I, Pape UF, Deprez PH, Bartsch DK, Caplin M, Falconi M, Garcia-Carbonero R, Grozinsky-Glasberg S, Jensen RT, Arnold R, Ruszniewski P, Toumpanakis C, Valle JW, O Toole D; Members of the Advisory Board of the European Neuroendocrine Tumor Society (ENETS). ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. J Neuroendocrinol 2022;:e13105. [PMID: 35233848 DOI: 10.1111/jne.13105] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
118 Smith D, Lepage C, Vicaut E, Dominguez S, Coriat R, Dubreuil O, Lecomte T, Baudin E, Venat Bouvet L, Samalin E, Santos A, Borie O, Bisot-Locard S, Goichot B, Lombard-Bohas C. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study. Adv Ther 2022;39:2731-48. [PMID: 35419649 DOI: 10.1007/s12325-022-02103-7] [Reference Citation Analysis]
119 Rodriguez-Freixinos V, Capdevila J, Pavel M, Thawer A, Baudin E, O'Toole D, Herrmann K, Welin S, Grozinsky-Glasberg S, de Herder WW, Valle JW, Herman J, Kolarova T, Bouvier C, Falconi M, Ferone D, Singh S. Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. Eur J Cancer 2021;144:200-14. [PMID: 33370645 DOI: 10.1016/j.ejca.2020.11.037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
120 Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol 2021;33:378-85. [PMID: 33973550 DOI: 10.1097/CCO.0000000000000740] [Reference Citation Analysis]
121 Yang Z, Liang J, Leng K, Shi G. Survival Benefit of Surgical Resection for Pancreatic Neuroendocrine Tumors With Oligometastatic Liver Metastasis: A Retrospective and Propensity Score-Matching Analysis. Front Oncol 2022;12:903560. [DOI: 10.3389/fonc.2022.903560] [Reference Citation Analysis]
122 Sampedro-Núñez M, Bouthelier A, Serrano-Somavilla A, Martínez-Hernández R, Adrados M, Martín-Pérez E, Muñoz de Nova JL, Cameselle-Teijeiro JM, Blanco-Carrera C, Cabezas-Agricola JM, Díaz JÁ, García-Centeno R, Aragones J, Marazuela M. LAT-1 and GLUT-1 Carrier Expression and Its Prognostic Value in Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2020;12:E2968. [PMID: 33066332 DOI: 10.3390/cancers12102968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
123 Zenovia S, Neculae E, Trifan AV, Dimache M, Fotea V, Sîngeap AM. Duodenal large-cell neuroendocrine carcinoma as unusual cause of acute pancreatitis. Arch Clin Cases 2020;7:15-21. [PMID: 34754922 DOI: 10.22551/2020.26.0701.10167] [Reference Citation Analysis]
124 Duan H, Baratto L, Laudicella R, Stracuzzi F, Baldari S, Iagaru A. Molecular imaging of pancreatic neoplasms. Clin Transl Imaging 2021;9:141-51. [DOI: 10.1007/s40336-020-00408-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Ciobanu OA, Martin S, Fica S. Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). Exp Ther Med 2021;22:1479. [PMID: 34765020 DOI: 10.3892/etm.2021.10914] [Reference Citation Analysis]
126 Havasi A, Sur D, Cainap SS, Lungulescu CV, Gavrilas LI, Cainap C, Vlad C, Balacescu O. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers. Int J Mol Sci 2022;23:1109. [PMID: 35163032 DOI: 10.3390/ijms23031109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Mosenia A, Ward C, Yee A, Qorbani A, Corvera C. Multifocal pancreatic PPoma in the setting of MEN1: Case report and review of literature. Int J Surg Case Rep 2021;83:106008. [PMID: 34118524 DOI: 10.1016/j.ijscr.2021.106008] [Reference Citation Analysis]
128 Kan J, Tian Y, Shao Y, Xu H, Li X, Tang Q. Role of the ratio of NSE serum concentration in evaluating the therapeutic effect on metastatic neuroendocrine neoplasms of the liver. Tumori 2021;:3008916211002272. [PMID: 33759643 DOI: 10.1177/03008916211002272] [Reference Citation Analysis]
129 Altieri B, Barrea L, Modica R, Bottiglieri F, de Cicco F, Muscogiuri G, Circelli L, Savarese G, Di Somma C, Savastano S, Colao A, Faggiano A. Vitamin D deficiency and tumor aggressiveness in gastroenteropancreatic neuroendocrine tumors. Endocrine 2021. [PMID: 34533768 DOI: 10.1007/s12020-021-02869-w] [Reference Citation Analysis]
130 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
131 Zhang X, Yang H, Xin Y, Yang Y, Lu H, Zhou X. Complete Response After Pre-Operative Transcatheter Arterial Chemoembolization for Unresectable Primary Hepatic Neuroendocrine Tumour: A Case Report and Literature Review. Front Oncol 2022;12:893403. [PMID: 35692743 DOI: 10.3389/fonc.2022.893403] [Reference Citation Analysis]
132 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Reference Citation Analysis]
133 Manneh Kopp R, Espinosa-Olarte P, Alonso-Gordoa T. Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging. Cancers (Basel) 2022;14:2514. [PMID: 35626118 DOI: 10.3390/cancers14102514] [Reference Citation Analysis]
134 Marini I, Sansovini M, Bongiovanni A, Nicolini S, Grassi I, Ranallo N, Monti M, DI Iorio V, Germanò L, Caroli P, Sarnelli A, Paganelli G, Severi S. Theragnostic in neuroendocrine tumors. Q J Nucl Med Mol Imaging 2021;65:342-52. [PMID: 34881852 DOI: 10.23736/S1824-4785.21.03426-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
135 Peng Y, Tan S, Zhu G, Fang C, He P, Peng F, Gan Y, Tian J, Su S, Yang X, Li B. Successful application of ICG fluorescence imaging technology in rectal neuroendocrine tumor liver metastasis. Photodiagnosis Photodyn Ther 2021;37:102653. [PMID: 34848376 DOI: 10.1016/j.pdpdt.2021.102653] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Krug S, Damm M, Garbe J, König S, Schmitz RL, Michl P, Schrader J, Rinke A. Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality. J Clin Med 2021;10:3023. [PMID: 34300189 DOI: 10.3390/jcm10143023] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
137 Półtorak-Szymczak G, Budlewski T, Furmanek MI, Wierzba W, Sklinda K, Walecki J, Mruk B. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods. Front Oncol 2021;11:670233. [PMID: 34211845 DOI: 10.3389/fonc.2021.670233] [Reference Citation Analysis]
138 Kreppel B, Gonzalez-Carmona MA, Feldmann G, Küppers J, Moon ES, Marinova M, Bundschuh RA, Kristiansen G, Essler M, Roesch F, Gaertner FC. Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours. Nuklearmedizin 2021. [PMID: 34256394 DOI: 10.1055/a-1521-8604] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Alonso-Gordoa T, Manneh R, Grande E, Molina-Cerrillo J. High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now? Curr Treat Options Oncol 2022. [PMID: 35501552 DOI: 10.1007/s11864-022-00983-z] [Reference Citation Analysis]
140 Naik M, Al-Nahhas A, Khan SR. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now. Cancers (Basel) 2022;14:761. [PMID: 35159027 DOI: 10.3390/cancers14030761] [Reference Citation Analysis]
141 Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol 2022;:JCO2200176. [PMID: 35649195 DOI: 10.1200/JCO.22.00176] [Reference Citation Analysis]
142 Fiz F, Viganò L, Gennaro N, Costa G, La Bella L, Boichuk A, Cavinato L, Sollini M, Politi LS, Chiti A, Torzilli G. Radiomics of Liver Metastases: A Systematic Review. Cancers (Basel) 2020;12:E2881. [PMID: 33036490 DOI: 10.3390/cancers12102881] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
143 Abdel-Rahman O, Ghosh S. A Real-World Study of the Incidence and Outcomes of Early-Onset Well-differentiated Neuroendocrine Neoplasms. Am J Clin Oncol 2022. [PMID: 35696696 DOI: 10.1097/COC.0000000000000925] [Reference Citation Analysis]
144 Chevalier B, Dupuis H, Jannin A, Lemaitre M, Do Cao C, Cardot-Bauters C, Espiard S, Vantyghem MC. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations. Front Endocrinol (Lausanne) 2021;12:678869. [PMID: 34025587 DOI: 10.3389/fendo.2021.678869] [Reference Citation Analysis]
145 Martin S, Fica S, Parfeni O, Popa L, Manuc T, Rizea O, Lupescu I, Gherghe M, Becheanu G, Croitoru A. Somatostatinoma and Neurofibromatosis Type 1-A Case Report and Review of the Literature. Diagnostics (Basel) 2020;10:E620. [PMID: 32825782 DOI: 10.3390/diagnostics10090620] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
147 Takayanagi D, Cho H, Machida E, Kawamura A, Takashima A, Wada S, Tsunoda T, Kohno T, Shiraishi K. Update on Epidemiology, Diagnosis, and Biomarkers in Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers (Basel) 2022;14:1119. [PMID: 35267427 DOI: 10.3390/cancers14051119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
148 Kiesewetter B, Riss P, Scheuba C, Mazal P, Kretschmer-Chott E, Haug A, Raderer M. Management of adrenocortical carcinoma: are we making progress? Ther Adv Med Oncol 2021;13:17588359211038409. [PMID: 34484430 DOI: 10.1177/17588359211038409] [Reference Citation Analysis]
149 Kiesewetter B, Mazal P, Kretschmer-Chott E, Mayerhoefer ME, Raderer M. Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice. ESMO Open 2022;7:100478. [PMID: 35525183 DOI: 10.1016/j.esmoop.2022.100478] [Reference Citation Analysis]
150 Ingenerf M, Kiesl S, Karim S, Beyer L, Ilhan H, Rübenthaler J, Seidensticker M, Ricke J, Schmid-Tannwald C. 68Ga-DOTATATE PET/CT and MRI with Diffusion-Weighted Imaging (DWI) in Short- and Long-Term Assessment of Tumor Response of Neuroendocrine Liver Metastases (NELM) Following Transarterial Radioembolization (TARE). Cancers (Basel) 2021;13:4321. [PMID: 34503131 DOI: 10.3390/cancers13174321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol 2021;22:1752-63. [PMID: 34793718 DOI: 10.1016/S1470-2045(21)00572-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Ahmadzadehfar H, Ilhan H, Lam MGEH, Sraieb M, Stegger L. Radioembolization, Principles and indications. Nuklearmedizin 2022;61:262-72. [PMID: 35354218 DOI: 10.1055/a-1759-4238] [Reference Citation Analysis]
153 Geenen L, Nonnekens J, Konijnenberg M, Baatout S, De Jong M, Aerts A. Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [177Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. Nucl Med Biol 2021;102-103:1-11. [PMID: 34242948 DOI: 10.1016/j.nucmedbio.2021.06.006] [Reference Citation Analysis]
154 Roseland ME, Francis IR, Shampain KL, Stein EB, Wasnik AP, Millet JD. Gastric neuroendocrine neoplasms: a primer for radiologists. Abdom Radiol (NY) 2022. [PMID: 35411433 DOI: 10.1007/s00261-022-03509-1] [Reference Citation Analysis]
155 Rizen EN, Phan AT. Neuroendocrine Tumors: a Relevant Clinical Update. Curr Oncol Rep 2022. [PMID: 35254612 DOI: 10.1007/s11912-022-01217-z] [Reference Citation Analysis]
156 Modlin IM. ASO Author Reflections: A Genomic Blood Test (NETest) that Informs you if the Patient has a Recurrence at the First Postoperative Visit. Ann Surg Oncol 2021. [PMID: 33876353 DOI: 10.1245/s10434-021-10044-8] [Reference Citation Analysis]
157 Takeda Y, Kobayashi N, Kessoku T, Okubo N, Suzuki A, Tokuhisa M, Miwa H, Udaka N, Ichikawa Y. Case reports: chemoradiotherapy for locally advanced neuroendocrine carcinoma of the gallbladder. Clin J Gastroenterol 2022. [PMID: 35653037 DOI: 10.1007/s12328-022-01645-1] [Reference Citation Analysis]
158 de Ponthaud C, Menegaux F, Gaujoux S. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know. Cancers (Basel) 2021;13:5969. [PMID: 34885079 DOI: 10.3390/cancers13235969] [Reference Citation Analysis]
159 Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With? Curr Oncol Rep 2021;23:80. [PMID: 33937962 DOI: 10.1007/s11912-021-01071-5] [Reference Citation Analysis]
160 Kroll L, Mathew A, Baldini G, Hosch R, Koitka S, Kleesiek J, Rischpler C, Haubold J, Fuhrer D, Nensa F, Lahner H. CT-derived body composition analysis could possibly replace DXA and BIA to monitor NET-patients. Sci Rep 2022;12:13419. [PMID: 35927564 DOI: 10.1038/s41598-022-17611-3] [Reference Citation Analysis]
161 Apostolidis L, Dal Buono A, Merola E, Jann H, Jäger D, Wiedenmann B, Winkler EC, Pavel M. Multicenter Analysis of Treatment Outcomes for Systemic Therapy in Well Differentiated Grade 3 Neuroendocrine Tumors (NET G3). Cancers (Basel) 2021;13:1936. [PMID: 33923759 DOI: 10.3390/cancers13081936] [Reference Citation Analysis]
162 Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V, Cadiot G, Tauveron I, Laboureau S, Do Cao C, Walter T, Petorin C, Blanchet O, Jannin A, Gu C, Faron M, Leteurtre E, Rousselet MC, Zakeyh JJ, Marchal A, Chatelain D, Beaulaton C, Hervieu V, Ducreux M, Scoazec JY, Baudin E. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. Eur J Cancer 2021;152:100-15. [PMID: 34090142 DOI: 10.1016/j.ejca.2021.04.030] [Reference Citation Analysis]
163 Zhang X, Lu L, Liu J, Liu W, Li L, Wei Y, Fan J, Ma L, Gong P. A Nomogram to Accurately Identify Pancreatic Neuroendocrine Tumors Metastasizing to Distant Organs: A Study Based on Two National Population-Based Cohorts From the United States and China. Clin Med Insights Oncol 2022;16:11795549221099853. [PMID: 35620244 DOI: 10.1177/11795549221099853] [Reference Citation Analysis]
164 Garcia-Alvarez A, Hernando Cubero J, Capdevila J. Drug Development in Neuroendocrine Tumors: What Is on the Horizon? Curr Treat Options Oncol 2021;22:43. [PMID: 33786683 DOI: 10.1007/s11864-021-00834-3] [Reference Citation Analysis]
165 Lahner H, Mathew A, Klocker AL, Unger N, Theysohn J, Rekowski J, Jöckel KH, Theurer S, Schmid KW, Herrmann K, Führer D. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy. Endocrine 2021. [PMID: 34480724 DOI: 10.1007/s12020-021-02859-y] [Reference Citation Analysis]
166 Xu Z, Wang L, Dai S, Chen M, Li F, Sun J, Luo F. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States. JAMA Netw Open 2021;4:e2124750. [PMID: 34554237 DOI: 10.1001/jamanetworkopen.2021.24750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Del Olmo-García MI, Prado-Wohlwend S, Bello P, Segura A, Merino-Torres JF. Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions. Cancers (Basel) 2022;14:584. [PMID: 35158852 DOI: 10.3390/cancers14030584] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
168 Sivandzadeh GR, Ejtehadi F, Shoaee S, Aminlari L, Niknam R, Taghavi AR, Geramizadeh B, Hormati A, Safarpour AR, Bagheri Lankarani K. Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors. BMC Gastroenterol 2021;21:238. [PMID: 34030644 DOI: 10.1186/s12876-021-01821-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
169 Pellat A, Cottereau AS, Terris B, Coriat R. Neuroendocrine Carcinomas of the Digestive Tract: What Is New? Cancers (Basel) 2021;13:3766. [PMID: 34359666 DOI: 10.3390/cancers13153766] [Reference Citation Analysis]
170 Koumarianou A, Alexandraki KI, Wallin G, Kaltsas G, Daskalakis K. Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocine Neoplasms: A Systematic Review. J Clin Med. 2020;9. [PMID: 32521677 DOI: 10.3390/jcm9061777] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
171 Van Den Heede K, Chidambaram S, Van Slycke S, Brusselaers N, Warfvinge CF, Ohlsson H, Nordenström E, Almquist M. Effect of primary tumour resection without curative intent in patients with metastatic neuroendocrine tumours of the small intestine and right colon: meta-analysis. British Journal of Surgery 2021. [DOI: 10.1093/bjs/znab413] [Reference Citation Analysis]
172 Li MX, Lopez-Aguiar AG, Poultsides G, Rocha F, Weber S, Fields R, Idrees K, Cho C, Maithel SK, Zhang XF, Pawlik TM. Surgical outcomes of gastro-entero-pancreatic neuroendocrine tumors G3 versus neuroendocrine carcinoma. J Surg Oncol 2022. [PMID: 35616186 DOI: 10.1002/jso.26928] [Reference Citation Analysis]
173 Xie Y, Zhang S, Liu X, Huang X, Zhou Q, Luo Y, Niu Q, Zhou J. Minimal apparent diffusion coefficient in predicting the Ki-67 proliferation index of pancreatic neuroendocrine tumors. Jpn J Radiol. [DOI: 10.1007/s11604-022-01262-5] [Reference Citation Analysis]
174 Yin F, Wu ZH, Lai JP. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(17): 1751-1767 [DOI: 10.3748/wjg.v28.i17.1751] [Reference Citation Analysis]
175 Uehara-Watanabe N, Okuno-Ozeki N, Minamida A, Nakamura I, Nakata T, Nakai K, Yagi-Tomita A, Ida T, Ikeda K, Kitani T, Yamashita N, Kamezaki M, Kirita Y, Matoba S, Tamagaki K, Kusaba T. Direct evidence of proximal tubular proliferation in early diabetic nephropathy. Sci Rep 2022;12:778. [PMID: 35039597 DOI: 10.1038/s41598-022-04880-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
176 Jepsen DNM, Fiehn AK, Garbyal RS, Engel U, Holm J, Federspiel B. Immunohistochemical Staining With Neuroendocrine Markers is Essential in the Diagnosis of Neuroendocrine Neoplasms of the Esophagogastric Junction. Appl Immunohistochem Mol Morphol 2021;29:454-61. [PMID: 33480601 DOI: 10.1097/PAI.0000000000000906] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
177 Modlin IM, Kidd M, Oberg K, Falconi M, Filosso PL, Frilling A, Malczewska A, Salem R, Toumpanakis C, Laskaratos FM, Partelli S, Roffinella M, von Arx C, Kudla BK, Bodei L, Drozdov IA, Kitz A. Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Ann Surg Oncol 2021. [PMID: 34008138 DOI: 10.1245/s10434-021-10021-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
178 Yozgat A, Kekilli M, Altay M. Time to give up traditional methods for the management of gastrointestinal neuroendocrine tumours. World J Clin Cases 2021; 9(29): 8627-8646 [PMID: 34734042 DOI: 10.12998/wjcc.v9.i29.8627] [Reference Citation Analysis]
179 Marini F, Giusti F, Brandi ML. Epigenetic-based targeted therapies for well-differentiated pancreatic neuroendocrine tumors: recent advances and future perspectives. Expert Rev Endocrinol Metab 2021;:1-13. [PMID: 34554891 DOI: 10.1080/17446651.2021.1982382] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Fragkou PC, Papadopoulos IA, Papadopoulos A, Kontoveros EA, Kaltsas G, Vassilara F. Rare Presentation of a Metastatic Pancreatic Neuroendocrine Neoplasm Presenting with Atrial Flutter. Eur J Case Rep Intern Med 2021;8:002216. [PMID: 33585343 DOI: 10.12890/2021_002216] [Reference Citation Analysis]
181 Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, Eiring RA, Gansen DN, Patton CM, Kendi AT. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology 2021;298:261-74. [PMID: 33231532 DOI: 10.1148/radiol.2020201745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
182 Vanoli A, Grami O, Klersy C, Milanetto AC, Albarello L, Fassan M, Luchini C, Grillo F, Spaggiari P, Inzani F, Uccella S, Parente P, Nappo G, Mattiolo P, Milione M, Pietrabissa A, Cobianchi L, Schiavo Lena M, Partelli S, Di Sabatino A, Sempoux C, Capella C, Pasquali C, Doglioni C, Sessa F, Scarpa A, Rindi G, Paulli M, Zerbi A, Falconi M, Solcia E, La Rosa S. Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases. Endocr Pathol 2022. [PMID: 35553369 DOI: 10.1007/s12022-022-09720-6] [Reference Citation Analysis]
183 Fazio N. Personalizing Multimodal Treatment in Patients With Pancreatic Neuroendocrine Tumors. JCO Oncol Pract 2020;16:729-30. [PMID: 33084501 DOI: 10.1200/OP.20.00749] [Reference Citation Analysis]
184 Lamarca A, Cives M, de Mestier L, Crona J, Spada F, Öberg K, Pavel M, Alonso-Gordoa T. Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment. World J Gastroenterol 2021; 27(10): 976-989 [PMID: 33776367 DOI: 10.3748/wjg.v27.i10.976] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Rinke A, Auernhammer CJ, Bodei L, Kidd M, Krug S, Lawlor R, Marinoni I, Perren A, Scarpa A, Sorbye H, Pavel ME, Weber MM, Modlin I, Gress TM. Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine? Gut 2021;70:1768-81. [PMID: 33692095 DOI: 10.1136/gutjnl-2020-321300] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
186 Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. Curr Treat Options Oncol 2022. [PMID: 35325412 DOI: 10.1007/s11864-022-00967-z] [Reference Citation Analysis]